Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
InhaleRx Limited ( (AU:NX1) ) has shared an announcement.
Nexalis Therapeutics has marked a key shift from preparation to active clinical execution in the March quarter, initiating a Phase 1 first-in-human trial of its inhaled IRX-616a for panic disorder and advancing the Phase 2 program of inhaled IRX-211 for breakthrough cancer pain. The company also finalised the Phase 1 protocol for oral SRX-25 for treatment-resistant depression, completed its rebrand from InhaleRx to Nexalis Therapeutics to reflect a broader pipeline, and reaffirmed that all three programs are progressing under a fully funded, disciplined development strategy aimed at achieving future regulatory approvals.
Management highlighted a focus on efficient trial execution, capital discipline and expanding market awareness as it targets multiple upcoming clinical milestones. The rebrand and pipeline diversification position Nexalis as a more comprehensive pain and mental health drug developer, with continued progress in site activation, patient recruitment readiness and structured IP planning expected to shape its near-term value proposition for investors and other stakeholders.
More about InhaleRx Limited
Nexalis Therapeutics Ltd is an Australian clinical-stage biopharmaceutical company focused on developing inhaled and oral therapeutics for pain management and mental health disorders. Its current pipeline includes IRX-211 for breakthrough cancer pain, IRX-616a for panic disorder and SRX-25, an oral esketamine asset targeting treatment-resistant depression, with a strategic emphasis on U.S. FDA approval pathways.
Average Trading Volume: 164,123
Technical Sentiment Signal: Sell
Current Market Cap: A$5.82M
For detailed information about NX1 stock, go to TipRanks’ Stock Analysis page.